Table 2.

Differentially expressed circulating miRNAs between low-risk (LR) and metastatic CRPC samples.

	No. of samples detected		Mean (Std) Raw Ct		Mean (Std) ΔCt*
miRNA	LR	CRPC	LR	CRPC	LR	CRPC	Fold** change	p-value
hsa-miR-375	26	25	26.3(1.7)	24.2(2.1)	5.4(2.3)	2.4 (2.5)	+8.0	<0.0001
hsa-miR-96	2	4	33.5(1.1)	31.9(1.0)	15.1(0.6)	9.6(1.0)	+45.3	0.0022
hsa-miR-892b	8	8	34.9(1.1)	34.3(1.1)	15(1.7)	11.7(2.2)	+9.9	0.004
hsa-miR-378*	15	13	31.8(2.2)	30.7(2.4)	11.3(2.8)	8.1(2.8)	+9.2	0.0057
hsa-miR-302b	5	4	33.1(2.7)	28.8(0.2)	12.9(3.6)	7.4(0.2)	+45.3	0.0192
hsa-miR-548c-3p	28	25	31.6(1.9)	31.9(1.6)	11.4(2.5)	9.9(1.7)	+2.8	0.0216
hsa-miR-124	4	4	32.3(1.5)	33.3(1.3)	13.5(1.3)	11.3(0.8)	+4.6	0.025
hsa-miR-141	16	18	31.7(2.5)	30.2(2.1)	10.6(4.0)	7.9(2.6)	+6.5	0.0276
hsa-miR-875-5p	24	20	34.1(3.2)	32.9(2.3)	13(3.2)	10.8(3.3)	+4.6	0.0287
hsa-miR-409-3p	27	24	28.6(3.6)	32.0(3.4)	7.5(5.1)	10.3(3.7)	−7.0	0.0297
hsa-miR-548a-3p	28	25	31.6(2.0)	31.1(1.1)	10.7(2.8)	9.2(1.7)	+2.8	0.0302
hsa-miR-623	13	15	33.8(2.1)	35.6(1.4)	12.9(2.0)	14.3(1.4)	−2.6	0.0362
hsa-miR-520d-5p	28	26	27.9(2.1)	27.5(1.7)	6.9(2.6)	5.6(1.9)	+2.5	0.0414
hsa-miR-489	8	8	33.7(3.3)	32.6(2.5)	13.6(3.1)	10.7(2.3)	+7.5	0.0466

^*normalized by subtracting the Ct value of U6(reference) from the Ct value of each miRNA

^**calculated as the relative value 2 ^{−(ΔCT (group1) −ΔCT (group2))}

Out of 669 miRNAs probed, the relative expression levels of 12 miRNAs were up-regulated (designated by (+) in fold change) in CRPC patient serum samples in comparison to the levels found in low-risk patient serum samples, while the expression level of two miRNAs were down-regulated (designated by the (−) in fold change). Bolded miRNAs were selected for further study. P-values were calculated based on the unpaired two-sided t-test, with a cut-point of 0.05.